Who cares? Well, companies pursuing allogeneic stem cell products should be very concerned by this finding. It means that off the shelf stem cells likely carry with them all of the good and bad genes from the donor into the host. This means that until we know everything there is know about the upside and downside of every gene, inserting new genes into people is a huge risk. It means allogeneic stem cells plays (embryonic, cord blood, and adult donor cells) are really gene therapy plays. While this may prove revolutionary for curing the most deadly diseases (like HIV or GVHD), where the benefits outweigh the unknown risks, for everyday diseases, the potential risks likely outweigh the benefits.